Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose, food-effect, and placebo-controlled study of oral AS-0871 in healthy adults
NL-OMON49497Active, not recruiting
- Sponsor
- Carna Biosciences, Inc.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of sofnobrutinib in inflammatory diseases, autoimmune disease, rheumatoid arthritis (RA) and 1 more (2 arms), sponsored by Carna Biosciences, Inc. Primary endpoint: Safety and tolerability. Started Feb 2020; status: active, not recruiting.
02
Drugs
sofnobrutinib
03
Conditions
inflammatory diseasesautoimmune diseaserheumatoid arthritis (RA)chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON49497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49497.